ABOUT
About Medicinal Wolverine
A field notebook kept on the BPC-157 TB-500 research record, worked one constituent at a time — what the studies show, where they stop, and exactly where regulated access stands.
What this notebook keeps
Medicinal Wolverine keeps a field notebook on the BPC-157 TB-500 "Wolverine" blend and its two constituents, logging what the peer-reviewed literature and the public FDA record actually establish. Nothing here is a clinic, a pharmacy, or a storefront: no product is sold, sourced, or dispensed, no clinician is on staff, and no line on these pages is medical advice or a treatment recommendation.
The notebook exists because the blend is talked about far more than it is documented. "Wolverine" pairs two distinct peptides, and most of what circulates about it fuses two separate literatures into one confident story. This log does the reverse: it runs each constituent on its own channel, tags every finding with the peptide it belongs to, and leaves the honest gaps in ink — no combination trial, a fragment-versus-full-length caveat on TB-500, a thin human record — rather than smoothing them away.
What "medicinal" means here
The word "medicinal" in this domain is editorial framing, not a claim about services. It signals the register we read in — what the blend's constituents have been studied for in a research and clinical-science context, and where regulated medicinal access actually stands under the FDA's 503A compounding framework. It is a position the publisher occupies relative to the literature, not an offer of treatment, consultation, diagnosis, or prescription. Nothing on this site is a recommendation to use either peptide.
We describe what was administered to which species at which dose by which route, and we report the present-tense regulatory status from FDA sources. We do not recommend human doses, we do not name pharmacies or vendors, and we do not describe ways to obtain a restricted substance outside the lawful framework.
How we source
Every quantitative claim on this site maps to a numbered citation: a peer-reviewed study or review for the science, and an FDA page for the regulatory and access facts. Where the evidence is preclinical, we say so. Where a finding rests on full-length Thymosin Beta-4 rather than the TB-500 fragment, we say so. Where there is simply no data — combination efficacy, blend pharmacokinetics, long-term human safety — we say that too, because a marked gap is more useful than a confident guess.